GHRH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
=== China (mainland) === The National Administration of Traditional Chinese Medicine was created in 1949, which then absorbed existing TCM management in 1986 with major changes in 1998. China's National People's Congress Standing Committee passed the country's first law on TCM in 2016, which came into effect on 1 July 2017. The new law standardized TCM certifications by requiring TCM practitioners to (i) pass exams administered by provincial-level TCM authorities, and (ii) obtain recommendations from two certified practitioners. TCM products and services can be advertised only with approval from the local TCM authority. Ready-to-use TCM preparations, also known as Chinese patent medicines, are regulated by the National Medical Products Administration (and its predecessor CFDA) similar to preparations used in modern medicine since 1984. The barrier for entry, however, is much lower than medications based on modern/non-TCM principles; the rules allow for omitting clinical testing in a variety of circumstances. As of 2025, the latest (2020) rules allow a simplified procedure for preparations derived from an approved list of "classic prescriptions". The government-run healthcare system covers a number of TCM procedures and preparations. In 2021, a total of 7114.5 billion yuan went into healthcare, amounting for 6.59% of the year's national GDP. Of these, 1111.5 billion yuan went into covering costs associated with TCM preparations (0.97% of national GDP), with 592.4 billion yuan covering the actual medications.
The diminished Byzantine state survived for another century through diplomacy and favourable external developments. The Ottomans gradually subjugated Anatolia and simultaneously expanded into Europe from 1354, taking Philippopolis in 1363, Adrianopolis in 1369, and Thessalonica in 1387. Dynastic struggles increasingly depended on Venetian, Genoese, and Ottoman backing. After Manuel II (r. 1391–1425) refused to pay homage to Sultan Bayezid I in 1394, Constantinople was besieged until the rampaging warlord Timur decisively defeated Bayezid in 1402, with the city perilously close to surrender. After Ankara, Manuel II gained nearly two decades of relative peace as Ottoman succession struggles and later Anatolian campaigns occupied the sultans. In 1421, his unsuccessful backing of the claimant Mustafa Çelebi led to a renewed Ottoman assault. Although John VIII (r. 1425–1448) reconciled with the Catholic West at the Council of Florence, his empire steadily diminished. In 1452, Sultan Mehmed II resolved to capture Constantinople, and laid siege early the following year. On 29 May 1453, the city was captured, the last emperor, Constantine XI, died in battle, and the Byzantine Empire ended.
22789Ac α (1.38%)→21.77 y 22387Fr β−→22 min 22388Ra α→11.4 d21986Rn The next element below francium (eka-francium) in the periodic table would be ununennium (Uue), element 119. The synthesis of ununennium was first attempted in 1985 by bombarding a target of einsteinium-254 with calcium-48 ions at the superHILAC accelerator at the Lawrence Berkeley National Laboratory in Berkeley, California. No atoms were identified, leading to a limiting yield of 300 nb.
At a growth rate of 2% per year, an industrial civilization should stop growing quite early in its history (after a few centuries). In summary, the impossibility of sustainably securing energy resources may explain the absence of Type II and III civilizations. For Zoltan Galántai, it is not possible to imagine a civilization project that spans centuries (like a Dyson sphere) or even millions of years, unless one imagines a thought and an ethic different from ours, within the reach of an ancestral civilization. He therefore proposes to classify civilizations according to their ability to carry out large-scale civilization projects over the long term. Finally, for Freeman Dyson, communication and life can continue forever in an open Universe with a finite amount of energy; intelligence is therefore the only fundamental parameter for a civilization to survive in the very long term, and energy is then no longer what defines it, a thesis he develops in his article "Time Without End: Physics and Biology in an Open Universe".
Sources: en.wikipedia.org
She also describes the legislation as a "slippery slope towards death on demand". 24 November – Alex Cole-Hamilton, the leader of the Scottish Liberal Democrats says his party will vote down the Scottish Government's upcoming budget if it contains even a "penny" promoting Scottish independence. 25 November – In an attempt to reassure industry there will not be further tax rises for business, Chancellor Rachel Reeves tells the CBI conference she is "not coming back with more borrowing or more taxes". An online petition calling for another general election reaches two million signatures, the third largest since 2010; in response, Starmer says he is "not that surprised" that people who did not vote for Labour would want an election re-run. South Wales politicians, including MP Sir Chris Bryant and MS Heledd Fychan, have criticised what they describe as a lack of preparation and insufficient warnings ahead of the arrival of Storm Bert. The Welsh Government publishes the Levy and Registration bill to allow councils in Wales to raise a tax from visitor accommodation, with the £1.25 per person per night levy expected to be introduced from 2027. 27 November – The UK government announces an overhaul of gambling laws, which will restrict the amount people can bet online with each bet to £5 for those aged over 25 and £2 for those aged 18 to 24. A Parliamentary Commission for Standards investigation is launched into Birmingham Yardley MP and Home Office minister Jess Phillips after she failed to register an interest on time.
147N + n → 126C + 31H Worldwide, the production of tritium from natural sources is about 4 megacuries (148 PBq) per year. The global equilibrium inventory of tritium created by natural sources remains approximately constant at 70 megacuries (2,590 PBq), as a balance between the fixed production rate and nuclear decay. These may be taken as 415 g and 7,250 g respectively.
Anne Ephrussi (born 15 September 1955 in Paris, France) is a French developmental and molecular biologist. Her research is focused on the study of post-transcriptional regulations such as mRNA localization and translation control in molecular biology as well as the establishment of polarity axes in cell and developmental biology. She is director of the EMBL International Centre for Advanced Training (EICAT) program at the European Molecular Biology Laboratory (EMBL) since 2005 and served as head of the Developmental Biology Unit from 2007 to 2021.
The NAD-I riboswitch (also called the nadA motif) was identified in species of the bacterial phylum Acidobacteriota, where it typically resides upstream of nadA genes encoding quinolate synthase, an enzyme in the de novo NAD⁺ biosynthesis pathway. Unusually, despite regulating genes relevant to NAD⁺ metabolism, neither binding domain of the NAD⁺-I riboswitch's dual-aptamer architecture has been shown to specifically recognize the nicotinamide portion of the coenzyme; instead, the RNA robustly binds the adenosine 5′-diphosphate (ADP) moiety of NAD⁺.
The addition of 1% cerium dioxide, as in gas mantles, heightens the effect by increasing emissivity in the visible region of the spectrum; but because cerium, unlike thorium, can occur in multiple oxidation states, its charge and hence visible emissivity will depend on the region on the flame it is found in (as such regions vary in their chemical composition and hence how oxidising or reducing they are). Several binary thorium chalcogenides and oxychalcogenides are also known with sulfur, selenium, and tellurium. All four thorium tetrahalides are known, as are some low-valent bromides and iodides: the tetrahalides are all 8-coordinated hygroscopic compounds that dissolve easily in polar solvents such as water. Many related polyhalide ions are also known. Thorium tetrafluoride has a monoclinic crystal structure like those of zirconium tetrafluoride and hafnium tetrafluoride, where the Th4+ ions are coordinated with F− ions in somewhat distorted square antiprisms. The other tetrahalides instead have dodecahedral geometry. Lower iodides ThI3 (black) and ThI2 (gold-coloured) can also be prepared by reducing the tetraiodide with thorium metal: they do not contain Th(III) and Th(II), but instead contain Th4+ and could be more clearly formulated as electride compounds. Many polynary halides with the alkali metals, barium, thallium, and ammonium are known for thorium fluorides, chlorides, and bromides.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.